Lupin has received approval for incorporation of a Wholly Owned Subsidiary (WOS) in the name and style ‘LUPINLIFE Consumer Healthcare’ or any other appropriate name, as may be approved by the Ministry of Corporate Affairs. The proposed New WOS will be incorporated with an objective to carry out the business of trading and manufacturing of various types of consumer healthcare products predominantly over the counter drugs and products.
The company has also received approval for transfer of the Over-the-Counter (OTC) Consumer Healthcare Business of the Company, on a slump sale basis, to a wholly owned subsidiary that is proposed to be incorporated.
The Board of Directors of the Company, at its meeting held on February 11, 2025, inter alia, considered and unanimously approved the same.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
